![[Aria Pharmaceuticals in PR Newswire] Aria Prescribed drugs presents constructive in vivo knowledge on lead idiopathic pulmonary fibrosis therapy candidate](https://blog.ourcrowd.com/wp-content/uploads/2017/09/PR_newswire.jpg "[Aria Pharmaceuticals in PR Newswire] Aria Prescribed drugs presents constructive in vivo knowledge on lead idiopathic pulmonary fibrosis therapy candidate")
BOSTON, Nov. 14, 2022 /PRNewswire/ — Aria Prescribed drugs, a pharmaceutical firm targeted on bringing first-in-class small molecules to market, at present introduced that its lead candidate for idiopathic pulmonary fibrosis (IPF), TXR-1002, demonstrated vital efficacy in new preclinical analysis. TXR-1002 represents a totally new novel mechanism of motion for the potential therapy of IPF. Knowledge was offered on the sixth Annual Antifibrotic Drug Improvement Summit on November 10 in Boston.
Learn extra right here.
The put up [Aria Pharmaceuticals in PR Newswire] Aria Prescribed drugs presents constructive in vivo knowledge on lead idiopathic pulmonary fibrosis therapy candidate appeared first on OurCrowd Weblog.
